Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event. (Aspirin)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01375400|
Recruitment Status : Unknown
Verified June 2011 by Central Hospital, Nancy, France.
Recruitment status was: Recruiting
First Posted : June 17, 2011
Last Update Posted : June 21, 2011
Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event.
The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences.
Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Stroke||Drug: Aspirin Biological: blood sample||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event.|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||July 2011|
- Drug: Aspirin
Administration of 300 mg of aspirin, per os.
- Biological: blood sample
2 blood samples will be performed
- Measure of platelet activity recovery within 24 hours after the first 300 mg oral dose of aspirin given at hospital at the acute phase of ischemic stroke [ Time Frame: 1 month ]We study laboratory parameters of the first 300 mg oral dose of aspirin given, within 48 hours, after ischemic cerebral event. For all patients, two blood sampling are performed, the first, during the third hour after aspirin intake and the second during the twenty-fourth hour. Platelet reactivity is studied on the basis of serum thromboxane B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.
- Measure of effect of the first 300 mg oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated [ Time Frame: 1 month ]For patients already treated with a daily dose of aspirin, a supplementary withdrawn was done before aspirin intake. Platelet reactivity was studied on the basis of serum thromboxane B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01375400
|Contact: Sébastien Richard, MD||3 83 85 16 56 ext 0 firstname.lastname@example.org|
|Nancy, France, 54035|
|Contact: Sébastien Richard, MD 3 83 85 16 56 ext 33 0 email@example.com|
|Principal Investigator: Sébastien Richard, MD|